Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
Fig 8
Antitumor activity in various mouse xenograft models after treatment with ARQ 092 or ARQ 751.
(A) AN3CA xenograft model treated with ARQ 092, (B) AN3CA xenograft model treated with ARQ 751, (C) KPL-4 xenograft model treated with ARQ 092, (D) ZR-75-1 xenograft model treated with ARQ 092, (E) KPL-4 xenograft model treated with ARQ 092 as a single agent or combined with trastuzumab or paclitaxel, (F) A PDX melanoma model (ST052C) that contained Braf V600E and PIK3CA (H1047R) mutations treated with ARQ 092 as a single agent or combined with trametinib.